RSLS — ReShape Lifesciences Share Price
0.000.00%
Last trade - 00:00- $4.49m
- $2.12m
- $8.68m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.01 | ||
| Price to Tang. Book | 1.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -253.84% | ||
| Return on Equity | -177.64% | ||
| Operating Margin | -143.5% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.28 | 1.59 | 13.6 | 11.24 | 8.68 | 9.99 | 11.99 | -0.95% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Directors
- Dan Gladney CHM (68)
- Andrew Rasdal PRE (61)
- Thomas Stankovich CFO (60)
- Michael Bordainick SVP
- Gary Blackford LED (64)
- Barton Bandy DRC (59)
- Lori McDougal DRC (60)
- Arda Minocherhomjee DRC (68)
- Lesley Howe IND (76)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- January 2nd, 2008
- Public Since
- October 6th, 2016
- No. of Shareholders
- 34
- No. of Employees
- 31
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 23,457,090
- Address
- 1001 CALLE AMANECER, SAN CLEMENTE, 92673
- Web
- https://www.reshapelifesciences.com/obalon/
- Phone
- +1 9494296680
- Contact
- Thomas Stankovich
- Auditors
- RSM US LLP
Upcoming Events for RSLS
Q3 2024 ReShape Lifesciences Inc Earnings Release
Similar to RSLS
Accelerate Diagnostics
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
Agendia NV
NASDAQ Capital Market
FAQ
What is the ReShape Lifesciences share price?
As of Today at 22:57 UTC, shares in ReShape Lifesciences are trading at $0.20. This share price information is delayed by 15 minutes.
How has the ReShape Lifesciences share price performed this year?
Shares in ReShape Lifesciences last closed at $0.20 and the price had moved by -89.15% over the past 365 days. In terms of relative price strength the ReShape Lifesciences share price has underperformed the S&P500 Index by -91.37% over the past year.
What are the analyst and broker recommendations for ReShape Lifesciences?
The overall consensus recommendation for ReShape Lifesciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the ReShape Lifesciences dividend yield?
ReShape Lifesciences does not currently pay a dividend.
Does ReShape Lifesciences pay a dividend?
ReShape Lifesciences does not currently pay a dividend.
When does ReShape Lifesciences next pay dividends?
ReShape Lifesciences does not currently pay a dividend.
How do I buy ReShape Lifesciences shares?
To buy shares in ReShape Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of ReShape Lifesciences?
As of the previous close price of $0.20, shares in ReShape Lifesciences had a market capitalisation of $4.58m.
Where are ReShape Lifesciences shares listed?
Here are the trading details for ReShape Lifesciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: RSLS
What kind of share is ReShape Lifesciences?
Based on an overall assessment of its quality, value and momentum ReShape Lifesciences is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a ReShape Lifesciences share price forecast for 2024?
The analyst consensus target price for shares in ReShape Lifesciences is $1.00. That is 412.03% above the last closing price of $0.20.
Analysts covering ReShape Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.45 for the next financial year.
What is the trend in the ReShape Lifesciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ReShape Lifesciences. Over the past six months, its share price has underperformed the S&P500 Index by -42.64%.
As of the last closing price of $0.20, shares in ReShape Lifesciences were trading -24.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the ReShape Lifesciences PE Ratio?
The ReShape Lifesciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.20.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of ReShape Lifesciences?
ReShape Lifesciences' management team is headed by:
- Dan Gladney - CHM
- Andrew Rasdal - PRE
- Thomas Stankovich - CFO
- Michael Bordainick - SVP
- Gary Blackford - LED
- Barton Bandy - DRC
- Lori McDougal - DRC
- Arda Minocherhomjee - DRC
- Lesley Howe - IND